PT Kalbe Farma Tbk · IDX:KLBF

PT Kalbe Farma Tbk — FY2022 Earnings Presentation

43 slides from PT Kalbe Farma Tbk's earnings presentation, March 2023

  1. Slide 1: Company Update FY2022

    Riding the Recovery to Build a Healthier Nation Company Update FY2022 - Audited FY22 PT Kalbe Farma Tbk Maret 2023

  2. Slide 2: Forward-Looking Statement

    This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 31 December 2022 audited results of Forward-Looking the Company. The information contained in th

  3. Slide 3: Table of Content

    Table of Content Key Updates 4 Business Overview 10 Financial Overview 23 Appendix 29 THRIVE THROUGH INNOVATON & DIGITALIZATION

  4. Slide 4: Key Updates

    Key Updates THRIVE THROUGH INNOVATON & DIGITALIZATION

  5. Slide 5: Growth Areas

    Growth Innovation for Sustainable Growth Distribution Network & B2B Digital Areas Focus to perform innovation in all line of business: Initiatives Extensive distribution infrastructure and • Prescription Pharma: Specialty network to support internal group & 3rd Solid top line growth with category (o

  6. Slide 6: Market Challenges

    Market Challenges Economic Recovery Managing risks of high inflation, decreasing purchasing power, amidst interest rate hike and currency volatility Strategies to mitigate business risks from global uncertainty Supply Chain Adverse Impact Navigating the prolonged global supply chain issues by managi

  7. Slide 7: Focus on Customer Needs

    *international campaigns Focus on Customer Needs Provide extensive healthcare, including biologics products Expecting and services that catered to Clinical Mothers all life stages, locally and Lactating internationally Mothers Senior All life stages Adults Kids Teens 7 THRIVE THROUGH INNOVATON & DIG

  8. Slide 8: Strengthening our Human Capital

    Strengthening our Management Program • Kalbe Middle Management Program (KMMP) Human Capital • Kalbe First Line Management Program (KFMP) • Health & Mindfulness Meditation • Leader as Coach Committed to enhance skill and capacity of employees for Kampus Merdeka Program Collaborate with the Ministry o

  9. Slide 9: Access to Healthcare for a better life

    Access to Energy Efficiency Fight against stunting Healthcare for a Gradually moving towards energy efficiency and renewable energy Supporting nutrition for mothers and children in collaboration with BKKBN (National Family Planning Indonesia) and YARSI University better life Plastic waste & packagin

  10. Slide 10: Business Overview

    Dov KALBE Business Overview THRIVE THROUGH INNOVATION & DIGITALIZATION

  11. Slide 11: Corporate Overview

    Corporate Milestones Overview 1991 2022 1966 More than half a century of providing The largest publicly-listed Established, Listed in the Indonesia Stock wide-range healthcare solutions Exchange pharmaceuticals company in headquartered in Jakarta Southeast Asia market capitalization IDR 98.0 tn ($6.

  12. Slide 12: Prescription Pharmaceuticals

    Segment Breakdown Net Sales Prescription IDR bn (audited) Pharmaceuticals 6,149 + 7.5% Highlight Net Sales Growth Maintaining positive sales growth 5,719 (yoy) • Gross Profit Margin FY22 declined to 50.0% from in FY22 amidst declining Covid 52.8% in FY21 due to product mix and raw material cases pri

  13. Slide 13: Prescription Pharmaceuticals

    Segment Breakdown Oncology Products Prescription Pharmaceuticals Accelerating strategic collaborations, supporting the government program, and Biological based Products compliance to product quality standard Expanding Access to Healthcare National Health Insurance Program Other Products • Selection

  14. Slide 14: Prescription Pharmaceuticals

    Segment Breakdown Portfolio Prescription Strategy • Strengthening presence in specialty Novel Product Pharmaceuticals products through engagement with Focus on immuno- Clinical Development Strategic Partners Biologics Journey oncology products • Target acquisition of total 12-15 products • Genexine

  15. Slide 15: Consumer Health

    Segment Breakdown Net Sales Consumer IDR bn (audited) Health 4,153 ​+14.6% Highlight Net Sales Growth Maintaining positive top line (yoy) 3,623 • Gross Profit Margin FY22 declined to 56.2% from growth in FY22 59.0% in FY21 due to product mix and raw material price increase • Increase ASP 3% - 5% on

  16. Slide 16: Consumer Health

    Segment Breakdown Consumer Health Market Share 2022 Anti Cough Leveraging our strong brand and Antacids Diarrhea Remedies maintain customer loyalty 72% 56% 50% Promag Entrostop Komix, Woods Children Health Cold Multivitamin Supplement Remedies 52% 52% 39% Sakatonik ABC Extra Joss Mixagrip, Procold T

  17. Slide 17: Consumer Health

    Segment Breakdown Focus on herbal to enlarge portfolio New products development are focused on Consumer in the preventive category the multivitamin and mineral category Health Maintain strong brands with focus of preventive and Hevit Sakatonik Activ Xonce 1000 mg Fatigon development on herbal produc

  18. Slide 18: Consumer Health

    Segment Breakdown Consumer Red Ginger Health • Building red ginger ecosystem, Kalbe engages with more than 10,000 farmers across Herbal Development Indonesia • Conducting the development of tissue culture to produce superior and uniform red ginger seeds Indonesia’s signature natural resulting in a b

  19. Slide 19: Nutritionals

    Segment Breakdown Net Sales IDR bn (audited) Nutritionals 7,831 ​+ 9.3% Highlight Net Sales Growth 7,166 Maintaining positive top line (yoy) • Gross Profit Margin FY22 declined to 49.3% from growth in FY22 51.5% in FY21 due to product mix and raw material price increase • Increase ASP 3% - 5% on sel

  20. Slide 20: Nutritionals

    Segment Breakdown Nutritionals Expecting Lactating Extensive products coverage to Baby Toddler Kids Teens Adult Senior Clinical Mothers Mothers serve all ages and income groups new new new new new new new new new *New SKUs 20 THRIVE THROUGH INNOVATON & DIGITALIZATION

  21. Slide 21: Distribution & Logistics

    Segment Breakdown Net Sales Medical Distribution & IDR bn (audited) ​+ 10.8% Devices 6% Raw 10,801 Materials Net Sales Growth • Managed by PT Enseval Logistics 9,752 (yoy) Trading 9% Putera Megatrading Tbk Competitive advantage as the largest 3rd party (EPMT.JK), a listed distribution network in hea

  22. Slide 22: Distribution & Logistics

    Segment Breakdown The most extensive distribution network Distribution & • Explore selectively potential new 3rd party 72 Branches Logistics principals +200K Outlets • Continue to expand distribution Competitive advantage as the infrastructure and network largest distribution network in ⚬ Expand int

  23. Slide 23: Financial Overview

    Dov KALBE Financial Overview THRIVE THROUGH INNOVATION & DIGITALIZATION

  24. Slide 24: Consolidated Operational Performance

    Consolidated Net Sales Operational In IDR bn (audited) 10.2% Performance 28,934 Maintained a broad-based solid Growth yoy 26,261 growth 9.3% 10.8% 7.5% 14.6% 10,801 9,752 7,166 7,831 5,719 6,149 3,623 4,153 Prescription Consumer Health Nutritionals Distribution & Logistics Total Consolidated Net Sal

  25. Slide 25: Consolidated Operational Performance

    Growth yoy Margin in IDR bn (audited) Consolidated Operational Gross Profit Operating Expenses to Net Sales Net Income Performance 3.7% 2.9% 6.2% Maintained positive net profit 27.7% 25.8% growth amidst market challenges 12.1% 11.7% 43.0% 40.5% 1.1% 1.0% Selling 5.4% 5.0% Expenses G&A Expenses 11,28

  26. Slide 26: Working Capital Management

    Working Capital Management Managing Net Operating Cycle 163 Secure buffer stock amidst global • Net Operating Cycle has supply chain uncertainties increased from 129 days in FY21 130 129 147 to 163 days in FY22, mostly due 126 120 to inventory increase 122 • Strategy to increase buffer stock 111 109

  27. Slide 27: Capital Allocation

    Capital Total Debt & Gearing Ratio Cash & Net Cash Allocation Total Debt & Gearing Ratio Total Debt (IDR bn) Gearing Ratio Cash & cash equivalent Net Cash 1,200 7.0% Healthy gearing ratio with a 5.8% 5.8% 6,216 1,000 5.2% 6.0% 5,656 strong net cash to support 4.9% 5,208 5.0% business expansion 800 4

  28. Slide 28: Outlook

    Outlook YoY Sales Growth 2023 13-15% FY22: 10.2% Focus on innovation and digitalization EPS Growth 13-15% FY22: 7.1% Dividend Payout Ratio 45-55% Assumptions: • 14,800 USD/IDR exchange rate • 5.0% - 5.5% Indonesia GDP growth • Capex of IDR 1.0 Tn for production capacity, distribution, and network ex

  29. Slide 29: Appendix 1

    Appendix 1 THRIVE THROUGH INNOVATON & DIGITALIZATION

  30. Slide 30: Indonesia Macro Overview

    Indonesia Macro Overview GDP GROWTH (%) INFLATION (%) EXCHANGE RATE (Rupiah / USD) Consumer confidence is recovering overall 5.31% (YoY) CPI 5.47% (YoY) 15,731 As of 31 Dec 22 As of 28 Feb 23 As of 30 Dec 22 Estimated 2023 Estimated 2023 Estimated 2023 4.5-5.3% 3 ± 1% 14,800 – 15,200 The domestic ec

  31. Slide 31: Indonesia Macro Overview

    Handling the Covid Pandemic Roadmap National Health Insurance (JKN) Indonesia Macro • Testing, Tracing, Treatment for Covid-19 Patient Care (BPJS cost sharing) 300 Coverage 100% • Funding for vaccinations and encouraging people to be able to Overview self-vaccinate • Covid-19 Medicines, health worke

  32. Slide 32: Recent Pharma Regulations

    President Instruction No. 2 Year 2022 Recent Pharma • Acceleration to increase in the use of domestic products in the implementation of Government Procurement of Goods / Services Regulations Presidential Decree No. 10 Year 2021 regarding the investment sector Comply and benefit the • Traditional med

  33. Slide 33: Sustainability ESG Activities

    Sustainability ESG Activities Activities Provide access to healthcare and implementing a responsible business practices Red Ginger Farmers Solar Panel Kalbe Junior Scientist Award Empower the farmers and initiate Support energy efficiency by Provide opportunities to the Created Shared Value to reali

  34. Slide 34: Appendix 2

    Appendix 2 THRIVE THROUGH INNOVATON & DIGITALIZATION

  35. Slide 35: Financial Statement

    Financial Statement Dec 21 Dec 22 Change ytd BALANCE SHEET (Audited) (Audited) ASSETS CURRENT ASSETS Cash and Cash Equivalents 6,216,247,801,928 3,949,768,854,987 -36.5% Trade Receivables 3,431,018,099,213 4,613,623,001,325 34.5% Other Receivables 114,124,556,399 174,144,805,758 52.6% Other Current

  36. Slide 36: Financial Statement

    Financial Statement Dec 21 Dec 22 Change ytd BALANCE SHEET (Audited) (Audited) LIABILITIES CURRENT LIABILITIES Short-term Bank Loans - 705,600,000,000 Trade Payables 1,667,595,790,804 1,996,614,607,866 19.7% Other Payables 710,888,106,011 683,938,794,059 -3.8% Dividend Payables Accrued Expenses 551,

  37. Slide 37: Financial Statement

    Financial Statement Dec 21 Dec 22 Change ytd BALANCE SHEET (Audited) (Audited) EQUITY Capital Stock -Issued and Fully Paid 468,751,221,100 468,751,221,100 0.0% Additional Paid-in Capital, Net (34,118,673,814) (34,118,673,814) 0.0% Differences Arising from Transaction with Non-controlling Interests 3

  38. Slide 38: Financial Statement

    Financial Statement Dec 21 Dec 22 Change yoy PROFIT & LOSS (Audited) (Audited) NET SALES 26,261,194,512,313 28,933,502,646,719 10.2% COST OF GOODS SOLD (14,977,410,271,049) (17,229,436,210,443) 15.0% % to NS 57.0% 59.5% 4.4% GROSS PROFIT 11,283,784,241,264 11,704,066,436,276 3.7% Gross margin 43.0%

  39. Slide 39: Financial Statement

    Financial Statement Dec 21 Dec 22 Change yoy PROFIT & LOSS (Audited) (Audited) INCOME TAX BENEFIT (EXPENSES) (911,256,951,493) (1,008,813,493,059) 10.7% % to NS 3.5% 3.5% 0.5% INCOME FOR THE YEAR 3,232,007,683,281 3,450,083,412,291 6.7% % to NS 12.3% 11.9% -3.1% OTHER COMPREHENSIVE INCOME (LOSS) AFT

  40. Slide 40: Financial Statement

    Financial Statement Dec 21 Dec 22 Change yoy PROFIT & LOSS (Audited) (Audited) TOTAL COMPREHENSIVE INCOME FOR THE YEAR 3,208,499,314,413 3,513,671,510,204 9.5% Income for the Year Attributable to: Owners of the Parent Company 3,183,621,310,043 3,382,209,769,015 6.2% Non-controlling Interests 48,386,

  41. Slide 41: Financial Statement

    Financial Statement CASH FLOWS STATEMENT Dec 21 Dec 22 Change yoy Audited Audited CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from Short-term Bank Loans 136,100,000,000 1,453,200,000,000 967.7% Receipt of Capital Contributions from Subsidiary’s non-controlling interests 1,227,271,550,000 17,489,24

  42. Slide 42: Financial Statement

    Financial Statement CASH FLOWS STATEMENT Dec 21 Dec 22 Change yoy Audited Audited CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from Short-term Bank Loans 136,100,000,000 1,453,200,000,000 967.7% Receipt of Capital Contributions from Subsidiary’s non-controlling interests 1,227,271,550,000 17,489,24

  43. Slide 43: Thank You

    Thank You For further information: PT Kalbe Farma Tbk. Jalan Let. Jend. Suprapto Kav. 4 Jakarta 10510, Indonesia Tel. : 62-21-42873888 Fax. : 62-21-42873678 Email: syeren.amanda@kalbecorp.com investor.relations@kalbecorp.com Website: www.kalbe.co.id

PT Kalbe Farma — FY2022 Earnings Presentation on 6ix